CERo Therapeutics Holdings, Inc. Common Stock (CERO) — Cash Flow-to-Debt Ratio
CERo Therapeutics Holdings, Inc. Common Stock (CERO) has a Cash Flow-to-Debt Ratio of -0.07x as of June 2026, meaning its operating cash flow of $-2.33 Million could theoretically repay 0% of its total liabilities ($32.41 Million) in one year. See CERo Therapeutics Holdings, Inc. Common free cash flow to debt ratio to measure the company's free cash flow as a share of total liabilities.
CF-to-Debt Ratio
Operating Cash Flow
Total Liabilities
Data as of
CERo Therapeutics Holdings, Inc. Common Stock Cash Flow-to-Debt Ratio (2021–2025)
Historical debt coverage capacity for CERo Therapeutics Holdings, Inc. Common Stock across 5 annual periods. For the full cash flow conversion analysis, see CERo Therapeutics Holdings, Inc. Common operating cash flow efficiency.
Annual Cash Flow-to-Debt Ratio for CERo Therapeutics Holdings, Inc. Common Stock (2021–2025)
Year-by-year debt coverage analysis for CERo Therapeutics Holdings, Inc. Common Stock. Check earnings quality score of CERo Therapeutics Holdings, Inc. Common to evaluate the quality of earnings relative to operating cash generation.
| Year | CF-to-Debt Ratio | Operating CF (USD) | Total Liabilities | YoY Change |
|---|---|---|---|---|
| 2025 | -1.77x | $-16.08 Million | $9.09 Million | ▼ -147.6% |
| 2024 | -0.71x | $-5.79 Million | $8.10 Million | ▼ -482.4% |
| 2023 | -0.12x | $-5.79 Million | $47.18 Million | ▼ -348.2% |
| 2022 | -0.03x | $-1.09 Million | $39.90 Million | ▲ +63.7% |
| 2021 | -0.08x | $-697.11K | $9.25 Million | — |